别嘌醇,临床注释-2,变异和临床注释数据

别嘌醇

临床注释ID

981419260

药物名称(英)

allopurinol

变异单倍型

HLA-B*58:01

基因

HLA-B

证据级别

1A

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Toxicity

表现型类别

毒性

分数

181.375

PMID计数

38

计数的证据

41

表现型

药物过敏；嗜酸性粒细胞增多和全身症状的药物反应；表皮坏死松解症，毒性；严重皮肤不良反应；Stevens-Johnson 综合征

表现型(英)

Drug Hypersensitivity;drug reaction with eosinophilia and systemic symptoms;Epidermal Necrolysis, Toxic;severe cutaneous adverse reactions;Stevens-Johnson Syndrome

最新日期

2021/3/24 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/981419260

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
959	*58:01	Patients with one or two copies of the HLA-B58:01 allele may have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with allopurinol as compared to patients with no HLA-B58:01 alleles or negative for the HLA-B*58:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of allopurinol-induced adverse reactions.

临床证据

id	证据的ID	总结
1780	1448256105	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.
1779	1448255668	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.
1778	1447949095	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with allopurinol.
1777	1447676605	HLA-B *58:01 is associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.
1776	1447672343	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.
1775	1445362018	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1774	1184998111	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.
1773	1184987721	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1772	1184756798	HLA-B *58:01 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.
1771	1184755884	HLA-B *58:01 is not associated with increased risk of Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in people with severe cutaneous adverse reactions.
1770	1184748340	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1769	1184470833	HLA-B *58:01 is not associated with risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.
1768	1184467886	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1767	1183685128	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol.
1766	1183685121	HLA-B *58:01 is associated with drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in men with Hyperuricemia.
1765	1183685113	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic when treated with allopurinol in children with Hyperuricemia.
1764	1183685103	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.
1763	1183685075	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol in men.
1762	1183682626	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.
1761	1183682555	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1760	1183682546	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol in men with Gout.
1759	1183682532	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Hyperuricemia.
1758	1183682459	HLA-B *58:01 is associated with increased risk of erythema exudativum multiforme or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.
1757	981420004	HLA-B 58:01/58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.
1756	981419988	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.
1755	981345654	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1754	981345647	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.
1753	981345642	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol.
1752	981345637	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.
1751	981345632	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1750	981345627	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.
1749	827919454	HLA-B *58:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.
1748	PA166105003	Annotation of CPIC Guideline for allopurinol and HLA-B
1610	1448429006	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1609	1446902249	HLA-B *58:01 is associated with Drug Hypersensitivity and Exanthema when treated with allopurinol.
1608	1451211440	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.
1607	1450342159	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic when treated with allopurinol.
1606	1449170079	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol.
1605	1448997619	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.
1604	1448624570	HLA-B *58:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.
1603	1448530471	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol.

临床病史

id	类型	评论
695	Update	CA score added as part of scoring system release. LOE assigned following curator review.
694	Update	Attached CPIC guideline and removed override. Altered text slightly. Added conflicting evidence statement.
693	Update	Removed two annotations on efficacy and PK.
692	Update	Level 1A due to CPIC guideline and score
691	Update	added PMID 32433341
690	Update	Added PMID 29392141
689	Create	Created

最新招商产品更多>>